Lazard Asset Management
NPCE icon

Lazard Asset Management’s Neuropace NPCE Stock Holding History

Lazard Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Buy
124,305
+11,078
+10% +$166K ﹤0.01% 993
2025
Q4 		$1.75M Buy
113,227
+8,138
+8% +$109K ﹤0.01% 926
2025
Q3 		$1.08M Buy
105,089
+26,204
+33% +$247K ﹤0.01% 1115
2025
Q2 		$878K Buy
78,885
+75,786
+2,445% +$948K ﹤0.01% 1341
2025
Q1 		$38K Sell
3,099
-308
-9% -$3.85K ﹤0.01% 2036
2024
Q4 		$38K Sell
3,407
-20
-0.6% -$174 ﹤0.01% 2022
2024
Q3 		$23K Buy
3,427
+1
+0% +$7 ﹤0.01% 1993
2024
Q2 		$25K Sell
3,426
-115
-3% -$1.16K ﹤0.01% 2005
2024
Q1 		$46K Sell
3,541
-388
-10% -$5.53K ﹤0.01% 1732
2023
Q4 		$40K Buy
+3,929
New +$31.3K ﹤0.01% 1947

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Lazard Asset Management's NPCE Position: Q1 2026 in Review

Lazard Asset Management increased its Neuropace (NPCE) stake by 9.8% in Q1 2026, buying an estimated $166K and bringing the position to 124,305 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Lazard Asset Management first reported a position in NPCE in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.75M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Lazard Asset Management held 124,305 shares of Neuropace worth $1.63M as of Q1 2026.
  • Lazard Asset Management bought 11,078 Neuropace shares in Q1 2026, an estimated $166K.
  • Neuropace made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #993 holding.
  • Lazard Asset Management first reported a position in Neuropace in Q4 2023 and has held it in 10 quarters since.
  • Lazard Asset Management's Neuropace position peaked at $1.75M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.